Penetration of piperacillin-tazobactam into cancellous and cortical bone tissues | Zendy

Stephen J. Incavo | Zendy; P J Ronchetti | Zendy; Jin Ho Choi | Zendy; Huali Wu | Zendy; Martina Kinzig | Zendy; F. Sörgel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Penetration of piperacillin-tazobactam into cancellous and cortical bone tissues

Author(s) -

Stephen J. Incavo,

P J Ronchetti,

Jin Ho Choi,

Huali Wu,

Martina Kinzig,

F. Sörgel

Publication year - 1994

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.38.4.905

Subject(s) - cancellous bone , piperacillin , tazobactam , piperacillin/tazobactam , cortical bone , penetration (warfare) , medicine , pharmacokinetics , chemistry , pharmacology , surgery , biology , bacteria , anatomy , operations research , engineering , pseudomonas aeruginosa , genetics

The penetration characteristics of piperacillin-tazobactam into cortical and cancellous bone tissues were investigated in 10 patients undergoing total hip replacement. The concentration ratios of piperacillin/tazobactam were 9.4 +/- 1.8 in cancellous bone tissue and 8.0 +/- 2.2 in cortical bone tissue, which were close to the 8:1 ratio of drugs administered. The mean ratios of drug concentrations in bone and plasma for cancellous and cortical tissue were 23 and 18%, respectively, for piperacillin and 26 and 22%, respectively, for tazobactam. The concentrations of tazobactam achieved are sufficient to exert anti-beta-lactamase activity and supportive of clinical trials involving bone and joint infections, including those caused by beta-lactamase-producing pathogens.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research